Treatment
Donanemab: NHS won’t fund new Alzheimer’s drug
Despite disappointment at Donanemab decision, NICE must consider funding to support dementia and carers.
Lecanemab UK license for Alzheimer’s, not recommended by NICE
Lecanemab drug treatment for early Alzheimers is licensed for UK use; NICE must consider funding to support dementia and carers.